Regeneron/$REGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
- Ticker
- $REGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15,410
- Headquarters
- Tarrytown, United States
- Website
- www.regeneron.com
Regeneron Metrics
BasicAdvanced
$80B
19.91
$40.43
0.19
$3.70
0.47%
Price and volume
Market cap
$80B
Beta
0.19
52-week high
$859.34
52-week low
$575.93
Average daily volume
732K
Dividend rate
$3.70
Financial strength
Current ratio
3.335
Quick ratio
3.806
Long term debt to equity
0.063
Total debt to equity
0.085
Dividend payout ratio (TTM)
8.74%
Interest coverage (TTM)
75.34%
Profitability
EBITDA (TTM)
4,702.4
Gross margin (TTM)
44.46%
Net profit margin (TTM)
27.86%
Operating margin (TTM)
26.87%
Effective tax rate (TTM)
16.21%
Revenue per employee (TTM)
$1,010,000
Management effectiveness
Return on assets (TTM)
6.53%
Return on equity (TTM)
14.04%
Valuation
Price to earnings (TTM)
19.91
Price to revenue (TTM)
5.356
Price to book
2.55
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
23.271
Free cash flow yield (TTM)
4.30%
Free cash flow per share (TTM)
34.593
Dividend yield (TTM)
0.46%
Forward dividend yield
0.47%
Growth
Revenue change (TTM)
9.29%
Earnings per share change (TTM)
1.91%
3-year revenue growth (CAGR)
7.03%
10-year revenue growth (CAGR)
12.82%
3-year earnings per share growth (CAGR)
2.25%
10-year earnings per share growth (CAGR)
20.22%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Analyst projections of the future price of Regeneron stock.
Bulls say / Bears say
Second-quarter revenue rose 17% and non-GAAP earnings per share rose 11%. Regeneron has also repaid its Sanofi development balance, which management says will lift collaboration profits from the third quarter. (Regeneron Pharmaceuticals)
EYLEA HD sales in the US rose 52% year on year, helping shift patients from the older EYLEA product to a higher-dose version with broader dosing flexibility. That transition could cushion the retinal franchise as the legacy drug faces competition. (Regeneron Pharmaceuticals)
Sanofi will pay Regeneron $1 billion upfront and may pay up to a further $7 billion in milestones for four next-generation immunology antibodies. The deal offers near-term cash and a route to develop future products while sharing costs and commercial risk. (Regeneron Pharmaceuticals)
Legacy EYLEA sales fell sharply in the second quarter as patients switched to EYLEA HD and cheaper biosimilars added competitive pressure. Further biosimilar launches could keep weighing on this established revenue stream. (Regeneron Pharmaceuticals)
Regeneron’s Phase 3 fianlimab combination with Libtayo failed to significantly improve progression-free survival against pembrolizumab in first-line advanced melanoma. The setback removes a potential growth opportunity and highlights the risk that late-stage pipeline bets may not deliver. (Fierce Biotech)
Management expects Dupixent growth to moderate in the second half of 2026 as recent launches become part of the comparison and year-on-year comparisons get tougher. That could slow momentum in a major driver of Regeneron’s collaboration revenue. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Upcoming events
No upcoming events
Regeneron News
AllArticlesVideos
Funds containing Regeneron
AllUSDEURGBP
Fund name | Fund size | $REGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 5.42% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 5.42% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 1.30% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 1.30% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.